We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Medical Center Collaborates with GenomeQuest

By LabMedica International staff writers
Posted on 14 Jan 2013
GenomeQuest, Inc. More...
(Westborough, MA, USA) a leader in sequence data management, and Beth Israel Deaconess Medical Center (BIDMC; Boston, MA, USA), a Harvard Medical School teaching hospital, are entering into a two-year collaboration to develop whole-genome analysis (WGA) applications for personalized health care. The announcement was made during the opening session of the World Health Forum, held at Harvard Medical School, on December 20, 2012, in Boston (MA, USA).

GenomeQuest will provide whole-genome data management and analysis capabilities for all next-generation sequencing projects in BIDMC’s dept. of pathology. GenomeQuest will also provide application programming interface (API) access and training to the department’s scientific investigators and applied mathematicians. BIDMC pathologists will develop clinical grade annotation methods and databases for diagnoses of cancers and other diseases. Collaborative projects will span user interface, workflows, sequence, and annotation management, and integration into health care Information Technology (IT) systems.

“The latest PriceWaterHouseCoopers report on personalized medicine estimates that this market will grow to nearly $500 billion in 2015 and terms it a ‘disruptive innovation’ for life sciences,” explained BIDMC chief of pathology Jeffrey Saffitz, MD, PhD. “The BIDMC pathology department is already a national leader in the development and application of genomics for personalized medicine, having launched its Genomic Medicine Training Initiative one year ago, and, this past spring, issuing a ‘Call to Action’ for pathology training programs across North America to do the same. Our collaboration with GenomeQuest helps provide us with the infrastructure to continue this work.”

Beth Israel Deaconess Medical Center is clinically affiliated with the Joslin Diabetes Center and is a research partner of the Dana-Farber/Harvard Cancer Center. The core technology of GenomeQuest is the GQ-Engine–a sequence database engine that is purpose-built for storing, managing, and analyzing sequence data at whole- and multigenome scale.

Related Links:
GenomeQuest, Inc.
Beth Israel Deaconess Medical Center


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Clinical Chemistry System
P780
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.